Nishit Agarwal, MS, is a Senior Data Science Engineer at Medidata, where he leverages his expertise in medical AI, wearable sensor technology, and biomedical signal processing to drive innovation in healthcare. Holding a master’s degree in bioengineering from Northeastern University, he specializes in extracting meaningful insights and novel biomarkers from various sensor modalities, including ECG, PPG, EMG, and EEG. Mr Agarwal has made significant contributions to the field of medical technology, particularly through his work on developing remote functional capacity tests using wearable sensor data. This innovative approach enables healthcare professionals to assess a patient's physical capabilities from anywhere in the world, revolutionizing how we conduct clinical trials and improving patient outcomes. Through his work at Medidata, Mr Agarwal has played a pivotal role in shaping the future of clinical trials, where technology and innovation converge to improve human health. His contributions are a testament to the power of interdisciplinary collaboration and the potential for wearable devices to transform our understanding of medical research.

Hicham Majd, PhD is leading device and packaging innovation in Global Device & Packaging Development (GDPD) at Novartis Pharma AG as Associate Director Science and Technology in Novel Solutions and Technologies and member of TRD Innovation Council. He has received his Master degree in Micro-Engineering and his PhD in Biotechnology and Bioengineering at EPFL, Switzerland and Business Certificate from Babson College, USA.

Mr Majd has a proven track record in technology innovation, with already multiple international patents, scientific publications and one book chapter. During his career, he leads device development in medical and no medical fields from idea to commercialization. Mr Majd developed and managed of novel bioreactor for cell culture that increases by 10-folds cell growth and preserves stem cells pluripotency.

Mr Majd worked at Helbling Technik Bern AG as specialist in bioengineering and material sciences. He founded and managed labseed SA, start-up developing a novel surface treatment for implantable device to improve the biocompatibility and bio-integration.

Will joined Zephyrus as COO in 2020. Prior to this, Will was CEO of a direct-to-consumer business, The London Sock Company. He began his career as a management consultant for Accenture where he advised a number of clients on Technology Transfer Programmes. Over the course of his career, Will has held a number of Senior roles focussing on strategy, estimation, planning and delivery with a wide variety of clients including Deutsche Bank, BBC, Thales, and BT. Will studied Natural Sciences at Bath University and went on to study law at University of London.

Jonathan Nolasco is a Senior Scientist at Novo Nordisk. Mr Nolasco holds a B.S from UC Berkeley (2016) and a Master’s from Harvard University (2020). Although formally trained as a cell biologist, he has worked extensively on developing non-viral delivery vehicles for prophylactic and gene therapy applications. He has worked on delivery vehicles for mRNA, self-amplifying mRNA, circular mRNA, siRNA, and Cas9/sgRNA. Mr Nolasco has worked on several projects ranging from early discovery to clinical. Prior to joining Novo Nordisk, he led a small team in the development of inhalable LNPs for the treatment of Cystic Fibrosis at Omega Therapeutics.

Penny Carlson has 27+ years of experience in the pharmaceutical industry and is currently Head of Global Clinical Development Operations, which includes Clinical Program Leadership, Study Management, Business Operations and Partnership Health and Supplier Management. Prior to this, Penny held various roles of increasing responsibility across several disciplines and multiple therapeutic areas. She started her career working for a small Contract Research Organization supporting NIH sponsored Vaccine and Infectious Disease studies, followed by several years working for large pharma in various data management roles, eventually transitioning to clinical operations in the Oncology therapeutic area, where she stayed for a number of years.

In 2011 Penny joined Takeda (previously Millennium) initially as a Clinical Program Manager and was later responsible for multiple assets in the early development space and was the Clinical Operations Lead for the Gastroenterology Therapeutic Area. For 5+ years, Penny has been an executive leader in the Global Development Organization, leading transformative initiatives for Takeda and focusing on clinical trial delivery, external partnerships and innovative ways of delivering medicines to patients.

Sheraz Khan is Director of Data Science at Pfizer. Sheraz lead operational-AI/ML group in AI/ML Quantitative and Digital Sciences. He obtained his PhD in Computational and Applied Mathematics from the Ecole Polytechnique, France, and has major interests in machine learning, Bayesian statistics and information geometry. He has over two decades of experience in developing signal processing and machine learning algorithms for multivariate time series data. Before joining Pfizer in 2022, he was an Assistant Professor at the Harvard University.

Venky Iyer is Director of Data Strategy & Automations within Information Management Group at Pfizer.  He has over three decades of experience in the pharmaceutical sector delivering key enablers for multiple clients to drive business value. Currently, he is actively involved in several AI/ML strategic initiatives partnering with key stakeholders and driving key concepts for enablement.  He holds a master’s degree in Mathematics and has been with Pfizer since 2019.

TBA

Matthieu is the head of Curadigm platform at Nanobiotix. He holds a doctorate in biotechnology. He has joined Nanobiotix in 2004. With over 15 years in nanomedicine, he is the author of more than 15 publications and scientific communications and is the inventor of 15 patents. He has held multiple positions in Nanobiotix and managed both domestic and international projects before taking the lead at Curadigm in 2018.

Mary Lou Glotzbach is a Business Development Executive for Grand River Aseptic Manufacturing (GRAM). Mary Lou’s career experience ranges from diagnostic and drug delivery devices through the manufacturing of injectable drugs. She is currently focused on combination products and the role of aseptic fill and finish manufacturing in the development and supply of drug delivery devices.